ANI Pharmaceuticals, Inc. (ANIP)Healthcare | Drug Manufacturers - Specialty & Generic | Baudette, United States | NasdaqGM
72.29 USD
+0.01
(0.014%)
⇧
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 72.29 |
Hot Take ↕ | Oct. 10, 2026, 2:57 a.m. EDT
ANI Pharmaceuticals presents a compelling long-term value story obscured by short-term technical weakness and a lack of income. Fundamentally, the company is a standout: it boasts robust revenue growth of nearly 26%, a massive 89% surge in earnings, and a pristine balance sheet with a current ratio of 2.91. The forward P/E of 7.1x suggests the market is pricing in significant future challenges, yet the business quality—driven by strong operating margins and cash generation—appears to be improving rapidly. However, the stock is currently trapped in a downtrend, trading below its 50-day and 200-day averages, which dampens immediate momentum. The absence of any dividend yield eliminates a floor for investors seeking income. While the statistical forecast models show low confidence due to recent price noise, the divergence between the deteriorating technicals and the accelerating fundamentals creates a classic 'value trap' setup that may resolve into a strong rebound once the market digests the earnings acceleration. The options market agrees with a potential upside move, betting on a recovery toward the 85-100 range over the coming year. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.049797 |
| AutoARIMA | 0.049797 |
| MSTL | 0.051583 |
| AutoTheta | 0.059984 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 4.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.444 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 104.825 |
| Revenue per Share | 47.241 |
| Market Cap | 1,660,526,720 |
| Trailing P/E | 15.78 |
| Forward P/E | 7.11 |
| Beta | 0.50 |
| Profit Margins | 11.07% |
| Website | https://www.anipharmaceuticals.com |
As of Oct. 10, 2026, 2:57 a.m. EDT: Speculators are positioning for a moderate upside move, evidenced by heavy open interest in out-of-the-money calls at strikes 85 and 100 for the January 2027 expiration, alongside significant volume in the 110 strike. Conversely, put activity is concentrated in deep out-of-the-money strikes (60) for the October 2026 expiry, suggesting a hedge against a sharp drop rather than a bearish bet on the trend. Implied volatility is elevated for near-term expirations, indicating uncertainty around the upcoming earnings date.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24001259 |
| Address1 | 210 Main Street West |
| All Time High | 450.0 |
| All Time Low | 4.8 |
| Ask | 103.53 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 353,180 |
| Average Daily Volume3 Month | 379,328 |
| Average Volume | 379,328 |
| Average Volume10Days | 353,180 |
| Beta | 0.495 |
| Bid | 56.91 |
| Bid Size | 2 |
| Board Risk | 1 |
| Book Value | 27.866 |
| City | Baudette |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 72.29 |
| Current Ratio | 2.91 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 73.08 |
| Day Low | 71.5 |
| Debt To Equity | 104.825 |
| Display Name | ANI Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,104,000 |
| Earnings Call Timestamp Start | 1,786,104,000 |
| Earnings Growth | 1.911 |
| Earnings Quarterly Growth | 1.891 |
| Earnings Timestamp | 1,786,105,800 |
| Earnings Timestamp End | 1,793,968,200 |
| Earnings Timestamp Start | 1,793,968,200 |
| Ebitda | 209,407,008 |
| Ebitda Margins | 0.21403 |
| Enterprise To Ebitda | 8.587 |
| Enterprise To Revenue | 1.838 |
| Enterprise Value | 1,798,203,648 |
| Eps Current Year | 9.26374 |
| Eps Forward | 10.16583 |
| Eps Trailing Twelve Months | 4.58 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 218 634 3540 |
| Fifty Day Average | 73.7288 |
| Fifty Day Average Change | -1.438797 |
| Fifty Day Average Change Percent | -0.019514723 |
| Fifty Two Week Change Percent | -24.001259 |
| Fifty Two Week High | 97.0 |
| Fifty Two Week High Change | -24.71 |
| Fifty Two Week High Change Percent | -0.25474226 |
| Fifty Two Week Low | 69.58 |
| Fifty Two Week Low Change | 2.709999 |
| Fifty Two Week Low Change Percent | 0.03894796 |
| Fifty Two Week Range | 69.58 - 97.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 957,533,400,000 |
| Float Shares | 19,661,341 |
| Forward Eps | 10.16583 |
| Forward P E | 7.1110773 |
| Free Cashflow | 132,205,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 970 |
| Fullday Change | 0.010002136 |
| Fullday Change Percent | 0.013838042 |
| Fullday Price | 72.29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.60403997 |
| Gross Profits | 590,980,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05415 |
| Held Percent Institutions | 1.07079 |
| Implied Shares Outstanding | 22,970,352 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://www.biosantepharma.com/SEC-Filings.php |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,374,105,600 |
| Last Split Factor | 1:6 |
| Long Business Summary | ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. |
| Long Name | ANI Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,660,526,720 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1528824 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 99,597,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,709,683,298 |
| Number Of Analyst Opinions | 9 |
| Open | 72.65 |
| Operating Cashflow | 189,466,000 |
| Operating Margins | 0.14974 |
| Overall Risk | 1 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.79 |
| Phone | 218 634 3500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 72.29 |
| Post Market Time | 1,792,180,855 |
| Previous Close | 72.28 |
| Price Eps Current Year | 7.803544 |
| Price Hint | 2 |
| Price To Book | 2.5942008 |
| Price To Sales Trailing12 Months | 1.6972224 |
| Profit Margins | 0.1107 |
| Quick Ratio | 2.297 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.77778 |
| Region | US |
| Regular Market Change | 0.0100021 |
| Regular Market Change Percent | 0.013838 |
| Regular Market Day High | 73.08 |
| Regular Market Day Low | 71.5 |
| Regular Market Day Range | 71.5 - 73.08 |
| Regular Market Open | 72.65 |
| Regular Market Previous Close | 72.28 |
| Regular Market Price | 72.29 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 333,921 |
| Return On Assets | 0.05446 |
| Return On Equity | 0.20459 |
| Revenue Growth | 0.259 |
| Revenue Per Share | 47.241 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 22,959,488 |
| Shares Percent Shares Out | 0.152 |
| Shares Short | 3,491,281 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,364,919 |
| Short Name | ANI Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1852 |
| Short Ratio | 8.36 |
| Source Interval | 15 |
| State | MN |
| Symbol | ANIP |
| Target High Price | 121.0 |
| Target Low Price | 85.0 |
| Target Mean Price | 105.77778 |
| Target Median Price | 104.0 |
| Total Cash | 376,961,984 |
| Total Cash Per Share | 17.591 |
| Total Debt | 626,028,032 |
| Total Revenue | 978,379,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 4.58 |
| Trailing P E | 15.783843 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 78.04045 |
| Two Hundred Day Average Change | -5.75045 |
| Two Hundred Day Average Change Percent | -0.073685504 |
| Type Disp | Equity |
| Volume | 333,921 |
| Website | https://www.anipharmaceuticals.com |
| Zip | 56,623 |